Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Meeuwes, Frederik O.; Brink, Mirian; Poel, Marjolein W. M. van der; Kersten, Marie José; Wondergem, Mariëlle J.; Mutsaers, Pim G.N.J.; Böhmer, Lara H.; Woei-A-Jin, F J Sherida H; Visser, Otto; Oostvogels, Rimke; Jansen, Patty M.; Diepstra, Arjan; Snijders, Tjeerd J.F.; Plattel, Wouter J.; Huls, Gerwin; Vermaat, Joost S.P.; Nijland, Marcel

doi:10.1016/j.ejca.2022.09.008

Cited by 6 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent publication, involving 335 AITL patients registered in the Netherlands Cancer Registry between 2014 and 2020, confirmed the findings previously cited by the French group. In the Dutch study, although addition of rituximab to CHOP-like regimens (CHOP-21 or CHOEP-21) improved ORR, there was no increase in OS or PFS with adoption of this strategy ( 130 ).…”

Section: Treatmentmentioning

confidence: 98%

Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances

et al. 2023

View full text Add to dashboard Cite

Angioimmunoblastic T-cell lymphoma (AITL) is the second most frequent subtype of mature T-cell lymphoma (MTCL) in the Western world. It derives from the monoclonal proliferation of T-follicular helper (TFH) cells and is characterized by an exacerbated inflammatory response and immune dysregulation, with predisposition to autoimmunity phenomena and recurrent infections. Its genesis is based on a multistep integrative model, where age-related and initiator mutations involve epigenetic regulatory genes, such as TET-2 and DNMT3A. Subsequently, driver-mutations, such as RhoA G17V and IDH-2 R172K/S promote the expansion of clonal TFH-cells (“second-hit”), that finally begin to secrete cytokines and chemokines, such as IL-6, IL-21, CXCL-13 and VEGF, modulating a network of complex relationships between TFH-cells and a defective tumor microenvironment (TME), characterized by expansion of follicular dendritic cells (FDC), vessels and EBV-positive immunoblasts. This unique pathogenesis leads to peculiar clinical manifestations, generating the so-called “immunodysplastic syndrome”, typical of AITL. Its differential diagnosis is broad, involving viral infections, collagenosis and adverse drug reactions, which led many authors to use the term “many-faced lymphoma” when referring to AITL. Although great advances in its biological knowledge have been obtained in the last two decades, its treatment is still an unmet medical need, with highly reserved clinical outcomes. Outside the setting of clinical trials, AITL patients are still treated with multidrug therapy based on anthracyclines (CHOP-like), followed by up-front consolidation with autologous stem cell transplantation (ASCT). In this setting, the estimated 5-year overall survival (OS) is around 30-40%. New drugs, such as hypomethylating agents (HMAs) and histone deacetylase inhibitors (HDAi), have been used for relapsed/refractory (R/R) disease with promising results. Such agents have their use based on a biological rationale, have significant potential to improve the outcomes of patients with AITL and may represent a paradigm shift in the therapeutic approach to this lymphoma in the near future.

show abstract

Section: Treatmentmentioning

confidence: 98%

Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[291][292][293][294][295] Blocking the PD-1/PDL-1 axis with monoclonal antibodies has shown promising results in some PTCL subtypes (Table 2). [296][297][298] PD-1/PD-L1 inhibitors in combination with chemotherapy or targeted therapy, have demonstrated significant clinical efficacy. Research on other immune checkpoints, including CTLA-4, TIM-3, LAG-3, and TIGIT, holds promise for identifying novel targets in immunotherapy.…”

Section: Extrinsic Pathogenic Mechanisms and Targeted Therapies Micro...mentioning

confidence: 99%

Precise diagnosis and treatment for peripheral T-cell lymphomas: From pathogenic mechanisms to innovative approaches

Qiu,

Zhao

2024

TIME

View full text Add to dashboard Cite

<p>Peripheral T-cell lymphomas (PTCLs) encompass a diverse group of aggressive non-Hodgkin��s lymphomas originating from mature T lymphocytes. Despite their relatively low prevalence compared to B-cell lymphomas, PTCLs pose significant clinical challenges due to their heterogeneity, lack of specific biomarkers, and often poor response to conventional chemotherapies. Unraveling the intricate pathogenic mechanisms underlying PTCLs is pivotal for the development of targeted therapies, which has become a major focus of PTCL research in recent years. It was previously postulated that genomic alterations play a pivotal role in T-cell transformation and lymphomagenesis. Recent multi-omics investigations and functional studies focusing on pathogenic mechanisms have unveiled that in addition to genetic abnormalities, diverse intrinsic and extrinsic mechanisms are implicated in the pathogenesis of PTCLs. In this Review, we provide an overview of the recent advances in the pathogenesis and management of PTCLs, focusing on the current and potential precise diagnosis and treatment based on intrinsic and extrinsic mechanisms. Bioengineering and drug development have enabled the effective modulation of many previously ��undruggable�� targets, which offers the potential to target new biomarkers associated with PTCL pathogenesis. The integration of artificial intelligence (AI) in clinical practice enables a comprehensive framework, merging diverse data sources and clinical context to discover precise biomarkers for personalized medicine. Finally, we present pressing questions and challenges that demand attention and discuss emerging solutions.</p>

show abstract

Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma

Zhang,

Yin,

Lai

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Cited by 6 publications

References 37 publications

Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances

Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances

Precise diagnosis and treatment for peripheral T-cell lymphomas: From pathogenic mechanisms to innovative approaches

Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma

Contact Info

Product

Resources

About